Pure Global

Lyra Direct SARS-CoV-2 Assay - India CDSCO Medical Device Registration

Lyra Direct SARS-CoV-2 Assay is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2020/000377_a7bf938cc3d9de09e029f0e5b7927791_e391db5a1f33e4983ba729a3278a6924. This device is marketed under the brand name Lyra SARS-CoV-2 Assay. The license holder is M/s Parekh Integrated Services Pvt. Ltd., and it is classified as Device Class Class C. The approving authority is CDSCO.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class C
Lyra Direct SARS-CoV-2 Assay
UID: IMP/IVD/2020/000377_a7bf938cc3d9de09e029f0e5b7927791_e391db5a1f33e4983ba729a3278a6924

Brand Name

Lyra SARS-CoV-2 Assay

Device Class

Class C

Approving Authority

CDSCO

Product Information

The Lyra Direct SARS-CoV-2 Assay is a real-time RT-PCR assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasal (Lyra SARS-CoV-2 Assay), nasopharyngeal (Lyra SARS-CoV-2 Assay), or oropharyngeal (Lyra SARS-CoV-2 Assay) direct swab specimens from patients suspected of COVID-19 by their healthcare provider.

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing